Celestia Higano

Dr. Celestia Higano


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2009 in Cancer
Verified
Journal Article
Closed access
PDF file
CHCelestia Higano
Celestia Higano
PSPaul F. Schellhammer
Paul F. Schellhammer
ESEric J. Small
Eric J. Small
PBPatrick A. Burch
Patrick A. Burch
JNJohn Nemunaitis
John Nemunaitis
MFMark W. Frohlich
Mark W. Frohlich

16 September 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MLMark P. Labrecque
Mark P. Labrecque
ICIlsa M. Coleman
Ilsa M. Coleman
LBLisha G. Brown
Lisha G. Brown
LTLawrence D. True
Lawrence D. True
LKLori Kollath
Lori Kollath
CMColm Morrissey
Colm Morrissey
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with diverse drivers of disease progression and mechanisms of therapeutic resistance. We conducted deep phenotypic characterization of CRPC metastases and patient-derived xenograft (PDX) lines using whole-genome RNA sequencing, gene set enrichment analysis, and immunohistochemistry. Our analyses revealed 5 mCRPC phenotypes based on the expression of well-characterized androgen receptor (AR) or neuroendocrine (NE) genes: AR-high tumors (ARPC), AR-low tumors (ARLPC), amphicrine tumors composed of cells coexpressing AR and NE genes (AMPC), double-negative tumors (i.e., AR–/NE–; DNPC), and tumors with small cell or NE gene expression without AR activity (SCNPC). RE1 silencing transcription factor (REST) activity, which suppresses NE gene expression, was lost in AMPC and SCNPC PDX models. However, knockdown of REST in cell lines revealed that attenuated REST activity drives the AMPC phenotype but is not sufficient for SCNPC conversion. We also identified a subtype of DNPC tumors with squamous differentiation and generated an encompassing 26-gene transcriptional signature that distinguished the 5 mCRPC phenotypes. Together, our data highlight the central role of AR and REST in classifying treatment-resistant mCRPC phenotypes. These molecular classifications could potentially guide future therapeutic studies and clinical trial design.

4 January 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MCMonique M Cherrier
Monique M Cherrier
PBPaul R Borghesani
Paul R Borghesani
ASAmy L Shelton
Amy L Shelton
CHCelestia Higano
Celestia Higano
A common treatment option for men with prostate cancer is androgen deprivation therapy (ADT). However, men undergoing ADT may experience physical side effects, changes in quality of life and sometimes psychiatric and cognitive side effects.

1 July 2010 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
CHCelestia Higano
Celestia Higano
ESEric J. Small
Eric J. Small
PSPaul Schellhammer
Paul Schellhammer
UYUma Yasothan
Uma Yasothan
SGSteven Gubernick
Steven Gubernick
PKPhilip W. Kantoff
Philip W. Kantoff

1 May 2022 in JCO Oncology Practice
Verified
Journal Article
Open access
KCKristin Campbell
Kristin Campbell
PCPrue Cormie
Prue Cormie
SWSarah Weller
Sarah Weller
SAShabbir Alibhai
Shabbir Alibhai
KBKate A. Bolam
Kate A. Bolam
JGJennifer Goulart
Jennifer Goulart
PURPOSE: Exercise has been underutilized in people with advanced or incurable cancer despite the potential to improve physical function and reduce psychosocial morbidity, especially for people with bone metastases because of concerns over skeletal complications. The International Bone Metastases Exercise Working Group (IBMEWG) was formed to develop best practice recommendations for exercise programming for people with bone metastases on the basis of published research, clinical experience, and expert opinion. METHODS: The IBMEWG undertook sequential steps to inform the recommendations: (1) modified Delphi survey, (2) systematic review, (3) cross-sectional survey to physicians and nurse practitioners, (4) in-person meeting of IBMEWG to review evidence from steps 1-3 to develop draft recommendations, and (5) stakeholder engagement. RESULTS: Recommendations emerged from the contributing evidence and IBMEWG discussion for pre-exercise screening, exercise testing, exercise prescription, and monitoring of exercise response. Identification of individuals who are potentially at higher risk of exercise-related skeletal complication is a complex interplay of these factors: (1) lesion-related, (2) cancer and cancer treatment–related, and (3) the person-related. Exercise assessment and prescription requires consideration of the location and presentation of bone lesion(s) and should be delivered by qualified exercise professionals with oncology education and exercise prescription experience. Emphasis on postural alignment, controlled movement, and proper technique is essential. CONCLUSION: Ultimately, the perceived risk of skeletal complications should be weighed against potential health benefits on the basis of consultation between the person, health care team, and exercise professionals. These recommendations provide an initial framework to improve the integration of exercise programming into clinical care for people with bone metastases.